|Podcasts|December 9, 2021

Episode 97: Diving Into Our 2022 Pipeline Report

Mike Ward, Global Head of Thought Leadership in the Decision Resources Group at Clarivate, goes behind the numbers of our 2022 pipeline report and provides some interesting insights from the report provided by his company.

Mike Ward, Global Head of Thought Leadership in the Decision Resources Group at Clarivate, discusses our 2022 pipeline report, appearing in our December issue. Mike goes behind the numbers and provides some interesting insights from the report provided by Clarivate.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.